Evidence map›Paper›PMID 25698644›Full record

ReviewNature reviews. Drug discovery2015

Principles in the design of ligand-targeted cancer therapeutics and imaging agents.

Madduri Srinivasarao, Chris V Galliford, Philip S Low

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Drug discovery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 221 papers.

0numbers the graph read from it
0cells of the map it votes in
221citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

221 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Tetrazine-Inorganic chemistry frontiers · 2026
    Article
  12. Optical and Optoacoustic Imaging Probes.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

161 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Madduri SrinivasaraoDepartment of Chemistry, 720 Clinic Drive, Purdue University, West Lafayette, Indiana 47907, USA.
Chris V GallifordDepartment of Chemistry, 720 Clinic Drive, Purdue University, West Lafayette, Indiana 47907, USA.
Philip S LowDepartment of Chemistry, 720 Clinic Drive, Purdue University, West Lafayette, Indiana 47907, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most cancer drugs are designed to interfere with one or more events in cell proliferation or survival. As healthy cells may also need to proliferate and avoid apoptosis, anticancer agents can be toxic to such cells. To minimize these toxicities, strategies have been developed wherein the therapeutic agent is targeted to tumour cells through conjugation to a tumour-cell-specific small-molecule ligand, thereby reducing delivery to normal cells and the associated collateral toxicity. This Review describes the major principles in the design of ligand-targeted drugs and provides an overview of ligand-drug conjugates and ligand-imaging-agent conjugates that are currently in development.

Indexed as

Drug DesignAnimalsAntineoplastic AgentsContrast MediaDrug Delivery SystemsHumansLigandsNeoplasmsAntineoplastic AgentsContrast MediaLigands

Identifiers

PMID25698644

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.